|
Personal Data: Name: Shu-Pin Huang M.D.& Ph.D. Address: Department of Urology, Kaohsiung Medical University,No. 100, Shih-Chuan 1 Road , Kaohsiung, TAIWAN 807
Marital Status: Married Birth Year: 1972Place of Birth: Kaohsiung, Taiwan |
|
Current Position:
Director, Graduate Institute of Clinical Medicine,
Kaohsiung Medical University,
No. 100, Tzyou 1st Road, Kaohsiung, TAIWAN 807
Phone: 886-7-3121101 ext. 6694
Mobile: 0935539310
Fax: 886-7-3211033
E-mail: shpihu73@gmail.com;shpihu@yahoo.com.tw
Education:
1. School of Medicine, Kaohsiung Medical University (KMU), 1990-1997 (M.D. Degree)
2. Graduate Institute of Medicine, Kaohsiung Medical University (KMU) 1999~2004 (Ph.D. Degree)
Post-Graduate Training:
1. Resident , Dept. of Urology, KMU 1997-1999
2. Chief Resident, Dept. of Urology, KMU, 2000
3. Visiting Staff, Dept. of Urology, KMU, 2000 ~ present
Postdoctoral Research
George Whipple Lab for Cancer Research, University of Rochester Medical Center, NY, USA, 2005~2006
Professional Society Membership:
1. Member of Taiwan Urological
|
Protocol Name and Number: Role: PI |
Study Period |
|
Protocol number.: 212082PCR3001 An Open-Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy. |
2012.09.01~2014.12.31 |
|
Protocol Number: MDV3100-14 PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. |
2013.11.01~2018.11.01 |
|
Protocol Number: 9785-CL-0232 Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy |
2014.05.01~2017.03.31 Top Recruiting Site |
|
Protocol Number: 9785-CL-0403 A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure (UPWARD) |
2014-7-30~2018-06-30 |
|
Protocol Number: ONC-MA-1001 A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men who are at High Risk for Poor Clinical Outcomes after Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men with Castration-Resistant Prostate Cancer and Men with Metastatic Prostate Cancer at Initial Diagnosis |
2015~ |
|
Protocol Number: Orion Pharma Protocol: 3104007 ARAMIS A Multinational, Randomized, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of ODM-201 in Men with High- Risk Non-Metastatic Castration-Resistant Prostate Cancer |
2015~ |
|
Protocol Number: MDV3100-13 A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy |
2016~ |
|
Bayer ARASENS 17777 study A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer |
2017~ |
|
Protocol Number: MVT-601-3201 HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer |
2017~ |
|
Protocol Number: 9785-CL-0335 ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) |
2017~ |
|
Protocol Number: CO39303 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER TRIAL TESTING IPATASERIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER |
2017~ 2018 |
|
Protocol Number: BAYER 21140 ARANOTE: A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC) |
2020 |
|
Protocol Number: C3441052 TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND,STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
|
2021 |
|
Protocol Number: Bayer Protocol 20510 RADIANT A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH. |
2021 |
|
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination with Cetrelimab(JNJ-63723283) versus Concurrent Chemoradiotherapy in Patients with Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy 17000139BLC3001 (Janssen) |
2022 |
Biography;
Prof/Dr. Shu-Pin Huang has received his PhD in Graduate of Medicine, Kaohsiung Medical University during the period of 1999 to 2004. Currently, he is working as Director of Graduate Institute of Clinical Medicine; Kaohsiung Medical University and Visiting Staff in Department of Urology, Kaohsiung Medical University Hospital in Taiwan. He is serving as a reviewer of several reputed journals like New England Journal of Medicine, Clinical Cancer Research, PLOS One, Cancer, Clinica Chimic Acta, Annals of Surgical Oncology, Journal of Endourology, International Journal of Oncology, Medicine, J Endourology, … etc. Prof Huang has published over 160 research articles in peer-review SCI journals. He is a member of Urological Association of Taiwan, American Urological Association (AUA) and European Association of Urology (EAU) and also served as Academic Editor for Medicine and Member of Editorial Board of International Journal of Urology. In additional to general Urology, Renal Transplantation and Robotic Surgery in Urology Oncology (majority on radical prostatectomy and Uro-oncology), Dr. Huang’s research interests were mainly focus on: Prostate Cancer, Molecular Epidemiology, Pharmacogenomic studies, Metabolic syndrome, Endocrine-Related Cancer, Urolithiasis, Andrology, Male Erectile dysfunction … etc.
Selected Published Papers:
1.
1. Chen JY+, Chang CF+, Huang SP+, Huang CY, Yu CC, Lin VC, Geng JH, Li CY, Lu TL, Bao BY. (2024, Jan). Integrated analysis identifies GABRB3 as a biomarker in prostate cancer. BMC Med Genomics. , 17(1):41. doi: 10.1186/s12920-024-01816-8..
2. Yuan-Chin Tsai*, Shu-Pin Huang*, Wei-Chung Cheng, Yu-Ching Fan, Ya-Ching Lin, Shin-Yu Tsai,Chao-Yuan Huang, Chia-Cheng Yu, Victor C Lin, Jiun-Hung Geng, Chia-Yang Li, Te-Ling Lu, Bo-Ying Bao (2024, Jan). Identifying the role of MTHFD1L in prostate cancer progression from genetic analysis and experimental validation. American Journal of Cancer Research, 14(1):169-181. eCollection 2024.. 本人為第一作者.
3. Chih-Yi Ho, Jia-In Lee, Shu-Pin Huang, Szu-Chia Chen and Jiun-Hung Geng (2023, Dec). A Genome-Wide Association Study of Metabolic Syndrome in the Taiwanese Population. nutrients, 16(1):77. doi: 10.3390/nu16010077..
4. Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF, Venugopal B, Woo HH, Ramirez-Backhaus M, Supiot S, Lantz A, Ganguli A, Ivanova J, Kral P, Huang SP, Saad F, Shore ND. (2023, Dec). Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evid, 2(12):EVIDoa2300251. doi: 10.1056/EVIDoa2300251. Epub 2023 Oct 22..
5. Pu YS, Huang CY, Wu HL, Wu JH, Su YF, Yu CR, Lu CY, Wu WJ, Huang SP, Huang YT, Hour TC. (2023, Nov). EGFR-mediated hyperacetylation of tubulin induced docetaxel resistance by downregulation of HDAC6 and upregulation of MCAK and PLK1 in prostate cancer cells. The Kaohsiung Journal of medical Sciences, doi: 10.1002/kjm2.12766. Online ahead of print..
6. Yazal T, Lee PY, Chen PR, Chen IC, Liu PL, Chen YR, Lin TC, Chen YT, Huang SP, Yeh HC, Liu CC, Lo J, Wu HE, Wang SC, Li CY. (2023, Nov). Kurarinone exerts anti-inflammatory effect via reducing ROS production, suppressing NLRP3 inflammasome, and protecting against LPS-induced sepsis. Biomedicine & Pharmacotherapy , 167:115619. doi: 10.1016/j.biopha.2023.115619..
7. Liu CC, Huang SP, Lee YC, Lee CH, Huang TY, Geng JH, Chang CW, Lin CY, Juan YS, Wu WJ, Hsieh TJ. (2023, Oct). Metabolic dysfunction-associated fatty liver disease is an early predictor for testosterone deficiency in aging men without metabolic syndrome. Frontiers in Endocrinology, 14:1252774. doi: 10.3389/fendo.2023.1252774..
8. Chang CF, Huang SP, Hsueh YM, Chen PL, Lee CH, Geng JH, Huang CY, Bao BY. (2023, Sep). CYBA as a Potential Biomarker for Renal Cell Carcinoma: Evidence from an Integrated Genetic Analysis. Cancer genomics & proteomics, 20(5):469-475.. 本人為通訊作者.
9. Chen YH, Lee JI, Shen JT, Wu YH, Tsao YH, Jhan JH, Wang HS, Lee YC, Huang SP, Chen SC, Geng JH (2023, Jun). The impact of secondhand smoke on the development of kidney stone disease is not inferior to that of smoking: a longitudinal cohort study. BMC public health, 23(1):1189. .
10. Lo J, Wu HE, Liu CC, Chang KC, Lee PY, Liu PL, Huang SP, Wu PC, Lin TC, Lai YH, Chang YC, Chen YR, Lee SI, Huang YK, Wang SC, Li CY. (2023, Apr). Nordalbergin Exerts Anti-Neuroinflammatory Effects by Attenuating MAPK Signaling Pathway, NLRP3 Inflammasome Activation and ROS Production in LPS-Stimulated BV2 Microglia. International Journal of Molecular Sciences, 24(8):7300. doi: 10.3390/ijms24087300..
11. Wu HE, Su CC, Wang SC, Liu PL, Cheng WC, Yeh HC, Chuu CP, Chen JK, Bao BY, Lee CH, Ke CC, Chen YR, Yu YH, Huang SP, Li CY. (2023, Apr). Anticancer Effects of Morusin in Prostate Cancer via Inhibition of Akt/mTOR Signaling Pathway. The American Journal of Chinese Medicine, 51(4):1019-1039. . 本人為通訊作者.
12. Yang CK, Cha TL, Chang YH, Huang SP, Lin JT, Wang SS, Huang CY, Pang ST. (2023, Apr). Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use. Journal of the Formosan Medical Association , 122(4):299-308..
13. Chen LC, Huang SP, Shih CT, Li CY, Chen YT, Huang CY, Yu CC, Lin VC, Lee CH, Geng JH, Bao BY. (2023, Mar). ATP8B1: A prognostic prostate cancer biomarker identified via genetic analysis. The Prostate, 83(6):602-611. . 本人為第一作者.
14. Chen YC, Chen HW, Huang TC, Chu TY, Juan YS, Long CY, Lee HY, Huang SP, Liu YP, Chen CJ, Wu MN, Chueh KS, Li CC, Lee CH, Tsai WC, Wu WJ. (2023). Skin sympathetic nerve activity as a potential biomarker for overactive bladder. World Journal of Urology, 41(5):1373-1379. .
15. Ou YJ, Lee JI, Huang SP, Chen SC, Geng JH, Su CH. (2023). Association between Menopause, Postmenopausal Hormone Therapy and Metabolic Syndrome. Journal of Clinical Medicine, 12(13):4435. doi: 10.3390/jcm12134435..
16. Chen YR, Wang SC, Huang SP, Su CC, Liu PL, Cheng WC, Chuu CP, Chen JK, Bao BY, Lee CH, Ke CC, Wu HE, Chang HH, Yeh HC, Li CY. (2022, Dec). Protodioscin inhibits bladder cancer cell migration and growth, and promotes apoptosis through activating JNK and p38 signaling pathways. Biomed Pharmacother. , Biomed Pharmacother. .
17. Huang CY, Lee JI, Chang CW, Liu YH, Huang SP, Chen SC, Geng JH. (2022, Dec). Chronic kidney disease and its association with cataracts-A cross-sectional and longitudinal study. Frontiers in Public Health, 10:1029962. doi: 10.3389/fpubh.2022.1029962. eCollection 2022..
18. Tang TY, Lee JI, Shen JT, Lee YC, Wang HS, Tsao YH, Wu YH, Huang SP, Chen SC, Jhan JH, Geng JH. (2022, Dec). The association between menopause, postmenopausal hormone therapy, and kidney stone disease in Taiwanese women. Ann Epidemiol. , S1047-2797(22)00305-2. .
19. Chang CF, Huang SP, Hsueh YM, Geng JH, Huang CY, Bao BY. (2022, Sep). Genetic Analysis Implicates Dysregulation of SHANK2 in Renal Cell Carcinoma Progression. Int J Environ Res Public Health. , 19(19):12471..
20. Chang CW, Lee JI, Huang CY, Lu CC, Liu YH, Huang SP, Chen SC, Geng JH. (2022, Sep). Habitual Tea Consumption and Risk of Cataracts: A Longitudinal Study. Int J Med Sci. , 19(10):1596-1602..
21. Lo J, Liu CC, Li YS, Lee PY, Liu PL, Wu PC, Lin TC, Chen CS, Chiu CC, Lai YH, Chang YC, Wu HE, Chen YR, Huang YK, Huang SP, Wang SC, Li CY. (2022, Sep). Punicalagin Attenuates LPS-Induced Inflammation and ROS Production in Microglia by Inhibiting the MAPK/NF-κB Signaling Pathway and NLRP3 Inflammasome Activation. J Inflamm Res., 15:5347-5359..
22. Wang BJ, Huang SH, Kao CL, Muller CJF, Wang YP, Chang KH, Wen HC, Yeh CC, Shih LJ, Kao YH, Huang SP, Li CY, Chuu CP. (2022, Jul). Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor. PLoS One., 17(7):e0270803. .
23. 17(7):e0270803. (2022, Jun). Regular Exercise Decreases the Risk of Osteoporosis in Postmenopausal Women. Front Public Health , 10:897363. .
24. Pu YS, Ahn H, Han W, Huang SP, Wu HC, Ma L, Yamada S, Suga K, Xie LP. (2022, Jun). Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study. Adv Ther., 39(6):2641-2656..
25. Chen YC, Liang YC, Ho SJ, Chen HW, Juan YS, Tsai WC, Huang SP, Lee JT, Liu YP, Kao CY, Lin YK, Long CY, Wu MN, Chen CJ, Wu WJ. (2022, May). Does COVID-19 Vaccination Cause Storage Lower Urinary Tract Symptoms?. J Clin Med., 11(10):2736. .
26. Li CY, Huang SP, Chen YT, Wu HE, Cheng WC, Huang CY, Yu CC, Lin VC, Geng JH, Lu TL, Bao BY. (2022, May). TNFRSF13B is a potential contributor to prostate cancer. Cancer Cell Ints, 22(1):180.. 本人為第一作者.
27. Yeh HC, Su CC, Wu YH, Lee CH, Bao BY, Cheng WC, Wang SC, Liu PL, Chiu CC, Chuu CP, Ke CC, Wu HE, Chen YR, Chung WJ, Huang SP, Li CY. (2022, May). Novel insights into the anti-cancer effects of 3-bromopyruvic acid against castration-resistant prostate cancer. J Pharmacol, 923:174929.. 本人為通訊作者.
28. Chen YC, Chen HW, Huang SP, Lin SH, Chu TY, Li CC, Juan YS, Wu WJ. (2022, Mar). Association of Warmer Weather and Infectious Complications Following Transrectal Ultrasound-Guided Prostate Biopsy. J Pers Med, 12(3):446. .
29. Lai YL, Liu CH, Wang SC, Huang SP, Cho YC, Bao BY, Su CC, Yeh HC, Lee CH, Teng PC, Chuu CP, Chen DN, Li CY, Cheng WC. (2022, Mar). Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis. Cancers (Basel), 14(6):1565.
30. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial (2022, Mar). Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. New England Journal Of Medicine, 386(12):1132-1142..
31. Liu CC, Wu CF, Lee YC, Huang TY, Huang ST, Wang HS, Jhan JH, Huang SP, Li CC, Juan YS, Hsieh TJ, Tsai YC, Chen CC, Wu MT. (2022, Jan). Genetic Polymorphisms of MnSOD Modify the Impacts of Environmental Melamine on Oxidative Stress and Early Kidney Injury in Calcium Urolithiasis Patients. Antioxidants (Basel)., 11(1):152. .
32. Chang CK, Lee JI, Chang CF, Lee YC, Jhan JH, Wang HS, Shen JT, Tsao YH, Huang SP, Geng JH. (2022, Jan). Betel Nut Chewing Is Associated with the Risk of Kidney Stone Disease. J Pers Med, 12(2): 126..
33. Hao-Han Chang, Cheng-Hsueh Lee, Yei-Tsung Chen, Chao-Yuan Huang, Chia-Cheng Yu,Victor C. Lin, Jiun-Hung Geng, Te-Ling Lu, Shu-Pin Huang, and Bo-Ying Bao (2022, Jan). Genetic Analysis Reveals the Prognostic Significance of the DNA Mismatch Repair Gene MSH2 in Advanced Prostate Cancer . Cancers (Basel), 14(1):223.. 本人為通訊作者.
34. Karunasinghe N, Minas TZ, Bao BY, Lee A, Wang A, Zhu S, Masters J, Goudie M, Huang SP, Jenkins FJ, Ferguson LR. (2022, Jan). Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions. Scientific reports, 12(1):55..
35. Chang CW, Ke HL, Lee JI, Lee YC, Jhan JH, Wang HS, Shen JT, Tsao YH, Huang SP, Geng JH. (2021, Nov). Metabolic Syndrome Increases the Risk of Kidney Stone Disease: A Cross-Sectional and Longitudinal Cohort Study. J Pers Med., 11(11):1154. .
36. Cheng KH, Geng JH, Lee CH, Liu CC, Wang CP, Huang SP. (2021, Nov). Potential Linkage between High Normalized Electromechanical Activation Time (EMAT), an Early Systolic Time Interval Abnormality with Metabolic Syndrome. Acta Cardiol Sin. , 37(6):625-631.. 本人為通訊作者.
37. Lee MR, Ke HL, Huang JC, Huang SP, Geng JH. (2021, Oct). Obesity-related indices and its association with kidney stone disease: a cross-sectional and longitudinal cohort study. Urolithiasis., doi: 10.1007/s00240-021-01288-w. Online ahead of print..
38. Teng PC, Huang SP, Liu CH, Lin TY, Cho YC, Lai YL, Wang SC, Yeh HC, Chuu CP, Chen DN, Cheng WC, Li CY. (2021, Oct). Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis. Int J Mol Sci., 22(21):11771..
39. Lee PY, Liu CC, Wang SC, Chen KY, Lin TC, Liu PL, Chiu CC, Chen IC, Lai YH, Cheng WC, Chung WJ, Yeh HC, Huang CH, Su CC, Huang SP, Li CY. (2021, Aug). Mycotoxin Zearalenone Attenuates Innate Immune Responses and Suppresses NLRP3 Inflammasome Activation in LPS-Activated Macrophages. Toxins (Basel), 13(9):593..
40. Huang CH, Wang SC, Chen IC, Chen YT, Liu PL, Fang SH, Huang SP, Yeh HC, Liu CC, Lee PY, Lin TC, Cheng WC, Su CC, Wu HE, Chen YR, Li CY. (2021, Jun). Protective Effect of Piplartine against LPS-Induced Sepsis through Attenuating the MAPKs/NF-κB Signaling Pathway and NLRP3 Inflammasome Activation. Pharmaceuticals (Basel), Jun 18;14(6):588. .
41. Huang SP, Chen LC, Chen YT, Lee CH, Huang CY, Yu CC, Lin VC, Lu TL, Bao BY. (2021, Jun). PTBP1 Genetic Variants Affect the Clinical Response to Androgen-deprivation Therapy in Patients With Prostate Cancer. Cancer Genomics Proteomics., 18(3):325-334.. 本人為第一作者.
42. Tsai YC, Huang CY, Hsueh YM, Fan YC, Fong YC, Huang SP, Geng JH, Chen LC, Lu TL, Bao BY. (2021, Jun). Genetic variants in MAPK10 modify renal cell carcinoma susceptibility and clinical outcomes. Life sciences, 275:119396.
43. Huang SP, Chen YT, Chen LC, Lee CH, Huang CY, Yu CC, Lin VC, Lu TL, Bao BY. (2021, May). NRG1 Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer. Biomedicines, 9(5):528. . 本人為第一作者.
44. Su CC, Wang SC, Chen IC, Chiu FY, Liu PL, Huang CH, Huang KH, Fang SH, Cheng WC, Huang SP, Yeh HC, Liu CC, Lee PY, Huang MY, Li CY. (2021, May). Zerumbone Suppresses the LPS-Induced Inflammatory Response and Represses Activation of the NLRP3 Inflammasome in Macrophages. Front Pharmacol. , 12:652860.
45. Wang SH, Huang SP, Pan YJ, Hsiao PC, Li CY, Chen LC, Yu CC, Huang CY, Lin VC, Lu TL, Bao BY. (2021, May). Association between the polygenic liabilities for prostate cancer and breast cancer with biochemical recurrence after radical prostatectomy for localized prostate cancer. Am J Cancer Res, 11(5):2331-2342.
46. Lin TY, Tsai MC, Tu W, Yeh HC, Wang SC, Huang SP, Li CY. (2021, Feb). Role of the NLRP3 Inflammasome: Insights Into Cancer Hallmarks. Frontiers in Immunology, Feb 3;11:610492.. 本人為通訊作者.
47. Liu CC, Huang SP, Hsieh TJ, Lee CH, Cheng KH, Huang TY, Geng JH, Li CC, Wu WJ, Lee YC. (2021, Feb). Fatty liver index is associated with the risk of testosterone deficiency in aging men without metabolic syndrome. Andrology, 9(3):863-872. .
48. Huang CY, Huang SP, Hsueh YM, Chen LC, Lu TL, Bao BY. (2020, Nov). Genetic Analysis Identifies the Role of HLF in Renal Cell Carcinoma. Cancer Genomics Proteomics., 17(6):827-833..
49. Li CC, Chien TM, Huang SP, Yeh HC, Lee HY, Ke HL, Wen SC, Chang WC, Juan YS, Chou YH, Wu WJ. (2020, Nov). Single-Site Sutureless Partial Nephrectomy for Small Exophytic Renal Tumors. J Clin Med., 9(11):3658..
50. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators (2020, Sep). Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med, 383(11):1040-1049..
51. Liu CC, Hsieh TJ, Wu CF, Lee CH, Tsai YC, Huang TY, Wen SC, Lee CH, Chien TM, Lee YC, Huang SP, Li CC, Chou YH, Wu WJ, Wu MT. (2020, Sep). Interrelationship of environmental melamine exposure, biomarkers of oxidative stress and early kidney injury. J Hazard Mater., 396:122726..
52. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. (2020, Jun). Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. , 382(23):2187-2196..
53. Ke CC, Chen LC, Yu CC, Cheng WC, Huang CY, Lin VC, Lu TL, Huang SP, Bao BY. (2020, May). Genetic Analysis Reveals a Significant Contribution of CES1 to Prostate Cancer Progression in Taiwanese Men. Cancers (Basel)., ;12(5):1346. . 本人為通訊作者.
54. Yu CC, Chen LC, Huang CY, Lin VC, Lu TL, Lee CH, Huang SP, Bao BY. (2020, Apr). Genetic association analysis identifies a role for ANO5 in prostate cancer progression. Cancer Med., 9(7):2372-2378. . 本人為通訊作者.
55. Yu CC, Chen LC, Lin WH, Lin VC, Huang CY, Lu TL, Lee CH, Huang SP, Bao BY. (2020, Mar). Genetic Association Analysis of Cell Cycle Regulators Reveals YWHAZ Has Prognostic Significance in Prostate Cancer. Cancer Genomics Proteomics. , 17(2):209-216.. 本人為通訊作者.
56. Lee CH, Chen LC, Yu CC, Lin WH, Lin VC, Huang CY, Lu TL, Huang SP, Bao BY. (2019, Nov). Prognostic Value of CD1B in Localised Prostate Cancer.. International Journal of Environment Research and Public Health, 16(23). pii: E4723. . 本人為通訊作者.
57. Yu CC, Chen LC, Lin VC, Huang CY, Cheng WC, Hsieh AR, Chang TY, Lu TL, Lee CH, Huang SP, Bao BY. (2019, Jun). Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy.. Cancer Medicine, 8(6): 2777–2783.. 本人為通訊作者.
58. Su CC, Hsieh KL, Liu PL, Yeh HC, Huang SP, Fang SH, Cheng WC, Huang KH, Chiu FY, Lin IL, Huang MY, Li CY (2019, Apr). AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway.. International Journal of Molecular Sciences, 20(7): 1647..
59. Yu CC, Chen LC, Chiou CY, Chang YJ, Lin VC, Huang CY, Lin IL, Chang TY, Lu TL, Lee CH, Huang SP, Bao BY. (2019, Apr). Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression. Cancer Cell International, 19: 87.. 本人為通訊作者.
60. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR1; ARAMIS Investigators. (2019, Mar). Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.. The New England Journal of Medicine, 380(13):1235-1246..